PFM Health Sciences’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-39,700
Closed -$13.6M 89
2023
Q1
$13.6M Buy
+39,700
New +$13.4M 0.6% 55
2016
Q4
Sell
-486,200
Closed -$39M 110
2016
Q3
$39M Buy
+486,200
New +$38.9M 1.14% 33

Other funds holding LLY

PFM Health Sciences's LLY Position: Q1 2026 in Review

PFM Health Sciences reduced its Eli Lilly (LLY) stake by 3.7% in Q1 2026, selling an estimated $2.56M and leaving 65,762 shares worth $60.5M. The position accounts for 5.52% of the portfolio, ranked #2.

PFM Health Sciences first reported a position in LLY in Q3 2015 and has held it in 24 quarters since. The position peaked at $270M in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • PFM Health Sciences held 65,762 shares of Eli Lilly worth $60.5M as of Q1 2026.
  • PFM Health Sciences sold 2,527 Eli Lilly shares in Q1 2026, an estimated $2.56M.
  • Eli Lilly made up 5.52% of PFM Health Sciences's portfolio in Q1 2026, its #2 holding.
  • PFM Health Sciences first reported a position in Eli Lilly in Q3 2015 and has held it in 24 quarters since.
  • PFM Health Sciences's Eli Lilly position peaked at $270M in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.